BIOTRONIK Creates Broader, Stronger PTA Balloon Portfolio
|
By HospiMedica International staff writers Posted on 29 Oct 2013 |
|
Image: The Passeo-35 HP 0.9 mm PTA balloon (Photo courtesy of BIOTRONIK).
New high-pressure percutaneous transluminal angioplasty (PTA) balloon lengths offer physicians the potential to dilate longer disease segments in lower limb vessels with fewer balloon inflations.
The Passeo-35 HP 0.9 mm PTA balloon is designed to treat vessel segments that require high pressure (HP) dilatation to efface resistant, often fibrotic stenosis, which are commonly encountered in arteriovenous (AV) access fistulae and grafts. The flexible balloon material is designed to conform to vessel curvature, minimizing vessel straightening during HP inflations. The Passeo-35 HP design aims to minimize axial and radial balloon expansion, avoiding excessive barotraumas, and providing excellent stability during inflation at high-rated burst pressures of up to 2735.7 kPa (27 atmospheres).
The BIOTRONIK Passeo-35 PTA balloon line extension and the Passeo-35 HP PTA balloon, intended for AV dialysis fistulae applications, are now available in lengths of up to 200 mm and in diameters of 3–7 mm. The new additions could help reduce potential barotrauma caused by multiple inflations, and may shorten procedure times. In addition, the Passeo-35 line has an extremely low profile, allowing for balloon compatibility with a 1.67 mm introducer sheath, and an excellent secondary profile.
The Passeo-35 line also has excellent synergies with other 0.889 mm guide wire compatible devices in the portfolio, such as the Dynamic Balloon Expandable Stent, the Astron Self Expanding Stent, and the Pulsar-35 Self Expanding Stent. The Passeo-35 HP is available in diameters from 3–12 mm and in balloon lengths from 20–100 mm. The Passeo-35 PA and Passeo-35 HP line of products is made by BIOTRONIK (Buelach, Switzerland).
“These latest additions to our unique peripheral intervention portfolio underline BIOTRONIK’s commitment to delivering dedicated, innovative devices in line with the needs and expectations of interventional operators,” said Alexander Uhl, vice president of marketing for vascular intervention at BIOTRONIK. “Furthermore, our PTA balloon portfolio is now one of, if not the, strongest and most comprehensive available.”
Related Links:
BIOTRONIK
The Passeo-35 HP 0.9 mm PTA balloon is designed to treat vessel segments that require high pressure (HP) dilatation to efface resistant, often fibrotic stenosis, which are commonly encountered in arteriovenous (AV) access fistulae and grafts. The flexible balloon material is designed to conform to vessel curvature, minimizing vessel straightening during HP inflations. The Passeo-35 HP design aims to minimize axial and radial balloon expansion, avoiding excessive barotraumas, and providing excellent stability during inflation at high-rated burst pressures of up to 2735.7 kPa (27 atmospheres).
The BIOTRONIK Passeo-35 PTA balloon line extension and the Passeo-35 HP PTA balloon, intended for AV dialysis fistulae applications, are now available in lengths of up to 200 mm and in diameters of 3–7 mm. The new additions could help reduce potential barotrauma caused by multiple inflations, and may shorten procedure times. In addition, the Passeo-35 line has an extremely low profile, allowing for balloon compatibility with a 1.67 mm introducer sheath, and an excellent secondary profile.
The Passeo-35 line also has excellent synergies with other 0.889 mm guide wire compatible devices in the portfolio, such as the Dynamic Balloon Expandable Stent, the Astron Self Expanding Stent, and the Pulsar-35 Self Expanding Stent. The Passeo-35 HP is available in diameters from 3–12 mm and in balloon lengths from 20–100 mm. The Passeo-35 PA and Passeo-35 HP line of products is made by BIOTRONIK (Buelach, Switzerland).
“These latest additions to our unique peripheral intervention portfolio underline BIOTRONIK’s commitment to delivering dedicated, innovative devices in line with the needs and expectations of interventional operators,” said Alexander Uhl, vice president of marketing for vascular intervention at BIOTRONIK. “Furthermore, our PTA balloon portfolio is now one of, if not the, strongest and most comprehensive available.”
Related Links:
BIOTRONIK
Gold Member
12-Channel ECG
CM1200B
New
Wound Irrigation Solution
Prontosan®
New
Blood Gas Analyzer
i-Check200
Latest Surgical Techniques News
- Ultrasound Technology Aims to Replace Invasive BPH Procedures
- Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
- New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
- Robot-Assisted Brain Angiography Improves Procedural Outcomes
- Brain Mapping Technology Enhances Precision in Brain Tumor Resection
- Handheld Robotic System Expands Options for Total Knee Surgery
- VR Experience Reduces Patient Anxiety Before Kidney Stone Procedure
- Injectable Mini Livers Offer Hope for Patients Awaiting Transplant
- Pulsed Field Ablation Technology Cleared in Europe for Persistent AFib
- AI-Powered Imaging Brings Real-Time Margin Clarity to Breast Cancer Surgery
- Minimally Invasive Device Safely Treats Challenging Brain Aneurysms
- Surgical Robot Makes Complex Liver Tumor Surgery Safer and Less Invasive
- Neurostimulation Implant Reduces Seizure Burden in Drug-Resistant Epilepsy
- Minimally Invasive Procedure Effectively Treats Small Kidney Cancers
- Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal
- Novel Hydrogel Could Become Bone Implant of the Future
Channels
Artificial Intelligence
view channel
AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
Critical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
